Neurogen is taking acharge of about $1.5 million in the first quarter of 2008 in connection withlaying off 70 workers. The payments will cover severance benefits and othercharges. According to Neurogen, the move is part of a restructuring to focusresources on advancing its pipeline of insomnia and other compounds includingPhase II candidate aplindore for Parkinson’s disease and restless legssyndrome.